Q1FY22 Earnings Presentation

8 Strides Regulated Markets • Market Q1FY22 Q4FY21 Q1FY21 QoQ% YOY% US1 3,016 4,273 3,738 -29% -19% Other Reg 2,232 2,722 2,606 -18% -14% Total 5,248 6,995 6,344 -25% -17% Emerging Markets Performance Overview Key Updates Regulated Markets US • US revenues at $41m for Q1FY22 versus $50m in Q1FY21, US contributed 44% of consolidated revenues in Q1FY22 Markets witnessed significant drop in prescription rates along with lower pharmacy footfalls and lesser number of elective surgeries Witnessed double digit price erosion in our portfolio with heightened competitive intensity Other Regulated Markets . • • Other regulated markets revenues at $30m for Q1FY22 versus $35m in Q1FY21, Other regulated markets contributed 32% of consolidated revenues in Q1FY22 Shutdown in the UK due to significant surge in Covid-19 cases led to lower prescription generations by ~20% for Rx and OTC products Supply disruptions from our manufacturing facilities due to increase in Covid-19 cases significantly impacted partnered business Business to bounce back in Q2FY22 and continue on its growth momentum Emerging Markets . • • Emerging markets revenues at $23m for Q1FY22 versus $20m in Q1FY21, business contributed 24% of consolidated revenues in Q1FY22 Institutional business was subdued during the quarter on account of lower off take of TLD Africa business delivered steady performance despite slowdown in certain markets Operating Cost • Logistics cost continued to be high during the quarter at *755m up 70% YoY, expect normalization in H2FY22 Puducherry update • Successful completion of the EU GMP inspection at Puducherry during Q1FY22. Market Q1FY22 Q4FY21 Q1FY21 QoQ% YoY% • Inst. Biz 970 1,448 810 -33% 20% Africa 701 671 693 4% 1% Total 1,671 2,119 1,503 -21% 11% Consolidated Group Revenues 5 Q1FY22 Total 6,919 Q4FY21 9,115 Q1FY21 7,847 QoQ% -24% YoY% -12% YoY comparison in INR reported • Awaiting facility inspection by the USFDA

View entire presentation